Nomogram for predicting survival after first-line anti-PD-1-based immunotherapy in unresectable stage IV melanoma: a multicenter international study
Open Access
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving Complete Response Under Anti-PD-1-Based ImmunotherapyAmerican Journal of Clinical Dermatology, 2023
- High serum LDH and liver metastases are the dominant predictors of primary cancer resistance to anti-PD(L)1 immunotherapyEuropean Journal of Cancer, 2022
- Outcomes Among Patients With or Without Obesity and With Cancer Following Treatment With Immune Checkpoint BlockadeJAMA Network Open, 2022
- Treatment of Advanced Melanoma in 2020 and BeyondJournal of Investigative Dermatology, 2021
- 1082MO 5-year characterization of complete responses in patients with advanced melanoma who received nivolumab plus ipilimumab (NIVO+IPI) or NIVO aloneAnnals of Oncology, 2020
- Site‐specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti–PD‐1 therapyCancer, 2019
- Association of Checkpoint Inhibitor–Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non–Small Cell Lung CancerJAMA Oncology, 2019
- Platelet-to-lymphocyte ratio in peripheral blood: A novel independent prognostic factor in patients with melanomaInternational Immunopharmacology, 2018
- RECIST 1.1—Update and clarification: From the RECIST committeeEuropean Journal of Cancer, 2016
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009